Trouble de la personnalité multiple : Questions médicales fréquentes
Nom anglais: Dissociative Identity Disorder
Descriptor UI:D009105
Tree Number:F03.300.500
Termes MeSH sélectionnés :
Double-Blind Method
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Trouble de la personnalité multiple : Questions médicales les plus fréquentes",
"headline": "Trouble de la personnalité multiple : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Trouble de la personnalité multiple : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-12",
"dateModified": "2025-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Trouble de la personnalité multiple"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Troubles dissociatifs",
"url": "https://questionsmedicales.fr/mesh/D004213",
"about": {
"@type": "MedicalCondition",
"name": "Troubles dissociatifs",
"code": {
"@type": "MedicalCode",
"code": "D004213",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "F03.300"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Trouble de la personnalité multiple",
"alternateName": "Dissociative Identity Disorder",
"code": {
"@type": "MedicalCode",
"code": "D009105",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Antje A T S Reinders",
"url": "https://questionsmedicales.fr/author/Antje%20A%20T%20S%20Reinders",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK."
}
},
{
"@type": "Person",
"name": "Eline M Vissia",
"url": "https://questionsmedicales.fr/author/Eline%20M%20Vissia",
"affiliation": {
"@type": "Organization",
"name": "Heelzorg, Centre for Psychotrauma, Zwolle, The Netherlands."
}
},
{
"@type": "Person",
"name": "Sima Chalavi",
"url": "https://questionsmedicales.fr/author/Sima%20Chalavi",
"affiliation": {
"@type": "Organization",
"name": "Movement Control and Neuroplasticity Research Group, Department of Movement Sciences, KU Leuven, Leuven, Belgium."
}
},
{
"@type": "Person",
"name": "Bethany L Brand",
"url": "https://questionsmedicales.fr/author/Bethany%20L%20Brand",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology."
}
},
{
"@type": "Person",
"name": "Ellert R S Nijenhuis",
"url": "https://questionsmedicales.fr/author/Ellert%20R%20S%20Nijenhuis",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical Engineering, King's College London, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Evaluating the effectiveness of stromal-vascular fraction (SVF) cells along with subcision method in the treatment of acne scars: A double-blind randomized controlled clinical trial study.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36086927",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jocd.15375"
}
},
{
"@type": "ScholarlyArticle",
"name": "ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.",
"datePublished": "2022-12-20",
"url": "https://questionsmedicales.fr/article/36600424",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-067251"
}
},
{
"@type": "ScholarlyArticle",
"name": "Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.",
"datePublished": "2022-05-23",
"url": "https://questionsmedicales.fr/article/35617986",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S2213-2600(22)00088-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.",
"datePublished": "2024-08-14",
"url": "https://questionsmedicales.fr/article/39161682",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/DDDT.S472651"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of Liposomal Melatonin in sleep EEG in Childhood: A Double Blind Case Control Study.",
"datePublished": "2022-12-29",
"url": "https://questionsmedicales.fr/article/36612875",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20010552"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Troubles mentaux",
"item": "https://questionsmedicales.fr/mesh/D001523"
},
{
"@type": "ListItem",
"position": 3,
"name": "Troubles dissociatifs",
"item": "https://questionsmedicales.fr/mesh/D004213"
},
{
"@type": "ListItem",
"position": 4,
"name": "Trouble de la personnalité multiple",
"item": "https://questionsmedicales.fr/mesh/D009105"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Trouble de la personnalité multiple - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Trouble de la personnalité multiple",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Trouble de la personnalité multiple",
"description": "Comment diagnostique-t-on ce trouble ?\nQuels critères sont utilisés pour le diagnostic ?\nLes tests psychologiques sont-ils nécessaires ?\nLe diagnostic est-il souvent tardif ?\nQui peut poser le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D009105?mesh_terms=Double-Blind+Method&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Trouble de la personnalité multiple",
"description": "Quels sont les symptômes principaux ?\nY a-t-il des symptômes physiques associés ?\nLes personnes peuvent-elles se souvenir de leurs identités ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLes crises de dissociation sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D009105?mesh_terms=Double-Blind+Method&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Trouble de la personnalité multiple",
"description": "Peut-on prévenir ce trouble ?\nLe soutien familial est-il important ?\nLes traumatismes peuvent-ils être évités ?\nLes programmes éducatifs aident-ils ?\nLa sensibilisation est-elle cruciale ?",
"url": "https://questionsmedicales.fr/mesh/D009105?mesh_terms=Double-Blind+Method&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Trouble de la personnalité multiple",
"description": "Quels traitements sont disponibles ?\nLes médicaments sont-ils efficaces ?\nLa thérapie de groupe est-elle bénéfique ?\nCombien de temps dure le traitement ?\nLa thérapie est-elle toujours nécessaire ?",
"url": "https://questionsmedicales.fr/mesh/D009105?mesh_terms=Double-Blind+Method&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Trouble de la personnalité multiple",
"description": "Quelles complications peuvent survenir ?\nLe risque de suicide est-il élevé ?\nLes relations sociales sont-elles affectées ?\nY a-t-il un risque d'abus de substances ?\nLes complications psychologiques sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D009105?mesh_terms=Double-Blind+Method&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Trouble de la personnalité multiple",
"description": "Quels sont les facteurs de risque principaux ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe stress chronique est-il un facteur ?\nLes événements traumatiques sont-ils déterminants ?\nLes troubles de l'attachement influencent-ils ?",
"url": "https://questionsmedicales.fr/mesh/D009105?mesh_terms=Double-Blind+Method&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on ce trouble ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation clinique des symptômes et l'exclusion d'autres troubles."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent la présence de deux identités et des lacunes de mémoire significatives."
}
},
{
"@type": "Question",
"name": "Les tests psychologiques sont-ils nécessaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests peuvent aider à évaluer la dissociation et à exclure d'autres troubles mentaux."
}
},
{
"@type": "Question",
"name": "Le diagnostic est-il souvent tardif ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diagnostic peut être retardé en raison de la méconnaissance du trouble par les professionnels."
}
},
{
"@type": "Question",
"name": "Qui peut poser le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un psychiatre ou un psychologue formé peut poser le diagnostic après une évaluation approfondie."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des identités distinctes, des amnésies et des changements d'humeur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes physiques associés ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes physiques peuvent apparaître, comme des douleurs ou des troubles somatiques."
}
},
{
"@type": "Question",
"name": "Les personnes peuvent-elles se souvenir de leurs identités ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, les individus ne se souviennent pas des actions de leurs autres identités."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la nature des symptômes peuvent varier considérablement entre les individus."
}
},
{
"@type": "Question",
"name": "Les crises de dissociation sont-elles fréquentes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les crises de dissociation peuvent survenir en réponse à des stress émotionnels."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir ce trouble ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention, mais un soutien psychologique précoce peut aider."
}
},
{
"@type": "Question",
"name": "Le soutien familial est-il important ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un soutien familial solide peut réduire le risque de développer des troubles dissociatifs."
}
},
{
"@type": "Question",
"name": "Les traumatismes peuvent-ils être évités ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les traumatismes dans l'enfance peut réduire le risque de développer le trouble."
}
},
{
"@type": "Question",
"name": "Les programmes éducatifs aident-ils ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes éducatifs sur la santé mentale peuvent sensibiliser et prévenir les troubles."
}
},
{
"@type": "Question",
"name": "La sensibilisation est-elle cruciale ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la sensibilisation au trouble peut aider à réduire la stigmatisation et favoriser le traitement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la thérapie cognitivo-comportementale et la thérapie par la parole."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de médicaments spécifiques, mais des antidépresseurs peuvent aider."
}
},
{
"@type": "Question",
"name": "La thérapie de groupe est-elle bénéfique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie de groupe peut offrir un soutien, mais elle n'est pas toujours appropriée."
}
},
{
"@type": "Question",
"name": "Combien de temps dure le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut durer des mois à des années, selon la gravité et la réponse au traitement."
}
},
{
"@type": "Question",
"name": "La thérapie est-elle toujours nécessaire ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie est généralement recommandée pour gérer les symptômes et améliorer la qualité de vie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles de l'humeur, des comportements suicidaires et des abus de substances."
}
},
{
"@type": "Question",
"name": "Le risque de suicide est-il élevé ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes de ce trouble présentent un risque accru de comportements suicidaires."
}
},
{
"@type": "Question",
"name": "Les relations sociales sont-elles affectées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les relations peuvent être gravement affectées en raison des comportements imprévisibles."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque d'abus de substances ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes peuvent avoir un risque accru d'abus de substances comme mécanisme d'adaptation."
}
},
{
"@type": "Question",
"name": "Les complications psychologiques sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles tels que l'anxiété et la dépression sont souvent associés au trouble."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque principaux ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents de traumatismes, d'abus ou de négligence durant l'enfance."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un historique familial de troubles mentaux peut augmenter le risque de développer le trouble."
}
},
{
"@type": "Question",
"name": "Le stress chronique est-il un facteur ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer au développement de troubles dissociatifs."
}
},
{
"@type": "Question",
"name": "Les événements traumatiques sont-ils déterminants ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des événements traumatiques graves, surtout durant l'enfance, sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "Les troubles de l'attachement influencent-ils ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles de l'attachement peuvent augmenter le risque de développer ce trouble."
}
}
]
}
]
}
Subcision method is one of the main techniques for treatment of acne scars or stromal-vascular fraction (SVF) and combined therapy can improve treatment strategy....
To use subcision method along with SVF for treatment of acne scar and comprised with alone subcision method....
In this double-blind clinical trial study, 10 patients with acne scars were entered into the study. Subcision technique was randomly performed on one side of the face and subcision technique plus SVF ...
In terms of volume and area of scars, the mean percent change was 46.55 ± 13.92 and 44.60 ± 5.76, for the case group, and 13.31 ± 9.27 and 11.28 ± 9.64 for the control group, respectively. So, combine...
According to the acquired results, combined therapy can be considered as effective and safe treatment for acne scars with significant higher efficacy compared with subcision alone....
Sepsis is a major cause of death among hospitalised patients. Accumulating evidence suggests that immune response during sepsis cascade lies within a spectrum of dysregulated host responses. On the on...
ImmunoSep is a randomised placebo-controlled phase 2 clinical trial with a double-dummy design in which the effect of precision immunotherapy on sepsis phenotypes with MALS and immunoparalysis is stud...
The protocol is approved by the German Federal Institute for Drugs and Medical Devices; the National Ethics Committee of Greece and by the National Organization for Medicines of Greece; the Central Co...
NCT04990232....
Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone p...
In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), a...
Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (...
In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in simi...
National Institute of Allergy and Infectious Diseases....
This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its efficacy and safety profile....
This prospective, double-blind, randomized controlled trial consisted of two cohorts. In cohort 1, 45 women aged 18-65 years undergoing hysteroscopy were randomly assigned to either group E (esketamin...
The ED95 of esketamine was 0.254 mg/kg (95% CI: 0.214-1.004), while that of alfentanil was 9.121 μg/kg (95% CI: 8.479-13.364). The anesthesia success rate was 93.0% in group E and 95.2% in group A (p ...
This study determined the ED 95 dose of esketamine for intravenous general anesthesia during hysteroscopy. Esketamine showed less respiratory and hemodynamic depression, as well as fewer adverse effec...
www.chictr.org.cn, (ChiCTR2300077283); registered November 3, 2023....
Electroencephalography (EEG) is pivotal in the clinical assessment of epilepsy, and sleep is known to improve the diagnostic yield of its recording. Sleep-EEG recording is generally reached by either ...
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that may advance to fibrosis and lead to mortality; however, no pharmacotherapy is currently available. We tested the hypothesis t...
To determine whether intravenous vitamin C compared with placebo, reduces vasopressor requirements in patients with vasoplegic shock....
Double-blinded, randomised clinical trial (RCT) conducted in two intensive care units in Perth, Australia. Vasopressor requirements at enrolment needed to be >10 μg/min noradrenaline after hypovolaemi...
Of the 71 patients randomised (35 vitamin C, 36 placebo group), the median vasopressor duration was 44 h [95% CI, 37-54 h] and 55 h [95% CI, 33-66 h]) in the vitamin C and placebo groups (p = 0.057). ...
In this RCT of patients with vasoplegic shock of at least moderate severity, the use of IV vitamin C compared with placebo did not significantly reduce the duration of vasopressors....
Prospective registration - trial number ACTRN12617001392358....
Fibrotic hypersensitivity pneumonitis (FHP) is an irreversible lung disease with high morbidity and mortality. We sought to evaluate the safety and effect of pirfenidone on disease progression in such...
We conducted a single-centre, randomised, double-blinded, placebo-controlled trial in adults with FHP and disease progression. Patients were assigned in a 2:1 ratio to receive either oral pirfenidone ...
After randomising 40 patients, enrolment was interrupted by the COVID-19 pandemic. There was no significant between-group difference in FVC% at week 52 (mean difference -0.76%, 95% CI -6.34 to 4.82). ...
The trial was underpowered to detect a difference in the primary end point. Pirfenidone was found to be safe and improved PFS in patients with FHP....
NCT02958917....
Pain after soft tissue injuries in and around the ankle is a troublesome process in terms of patient comfort and mobilization. The aim of this study was to compare the analgesic efficacy of intravenou...
We conducted a prospective, double-blind, randomized controlled study in a tertiary hospital. The patients were divided into two groups as those administered IV 400 mg ibuprofen and IV 20 mg tenoxicam...
One hundred and twenty-four patients were included in the study. There were 62 patients in the tenoxicam group and 62 patients in the ibuprofen group. When VAS scores were compared, it was found that ...